What the research found

The research-peptide market is increasingly using pharmaceutical development codes, abbreviated aliases, and supplier stock-keeping unit (SKU) designations instead of standard compound names—particularly for high-demand compounds like Retatrutide and Tirzepatide. The same molecule may circulate under multiple labels: Retatrutide appears as LY3437943 (Eli Lilly's official development code), GLP-3, R3TA, or RT30 depending on the source. Similar variation occurs with Tirzepatide (LY3298176, TR30, TR60). These naming shifts reflect three distinct sources: legitimate pharmaceutical R&D codes, reseller terminology, and supplier inventory systems—but they are often presented interchangeably in the market.

The shift is evident across creator-affiliated research-fulfilment businesses. A small sample of four major YouTube-based peptide educators and their linked suppliers showed inconsistent labeling for the same compounds: one used the straightforward name "Retatrutide," another used the Lilly code with a custom SKU, a third used "GLP-3 (R3TA)," and a fourth used "GLP-3 (Retatrutide)." This occurs alongside intensifying regulatory and commercial pressure—including Eli Lilly's August lawsuits and referrals to authorities—which may be driving terminology changes in the supply chain.

Why it matters for you

If you're sourcing peptides, you need to verify what you're actually receiving beyond the label. A compound listed as "RT30" or "GLP-3" may be claimed to be Retatrutide, but without independent testing (which the source notes is a separate cost layer), you're relying on supplier honesty. MyKine users who track protocol details and biomarker response should document exactly what name and code appeared on their order and COA (certificate of analysis), not just the common name. This creates a record if batch consistency or safety issues emerge later.

The naming opacity also matters for your data. If you log "Retatrutide" in your app but actually received something labeled "RT30" or "GLP-3," future protocol comparisons become unreliable. More importantly, if you need to communicate with a clinician or report an adverse event, you'll need to trace back through supplier codes to establish what the actual compound was. The proliferation of aliases makes this harder, not easier.

Caveats

  • No independent verification of contents: The article documents naming practices and SKU matching between suppliers, not laboratory testing of actual peptide identity or purity.
  • Preliminary market observation: This is descriptive reporting of supply-chain trends, not experimental evidence or clinical data.
  • Conflict of interest noted: The source itself is affiliated with RESURX Research, a supplier using these naming conventions, and discloses this relationship.
  • No data on intent: The article does not establish whether alternative naming is deliberate evasion or organic market adaptation. The distinction is stated but not resolved.
  • Unregulated market: All compounds discussed are research peptides, not approved medications, and regulatory status varies by jurisdiction.